| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -13,045,221 | -8,867,798 |
| Depreciation and amortization | 13,177 | 9,075 |
| Non-cash lease adjustments | 146,895 | - |
| Issuance of restricted stock for services | 134,100 | - |
| Stock-based compensation | 452,061 | 308,376 |
| Accretion of discounts on available for sale debt securities, net | 170,940 | 132,925 |
| Foreign currency remeasurement gain | 138,477 | 129,565 |
| Realized gain on redemptions of available for sale debt securities | 22,289 | 22,634 |
| Realized loss on equity securities | 214,925 | 142,248 |
| Unrealized gain on equity securities | 263,295 | 167,389 |
| Prepaid expenses and other current assets | -139,090 | 62,133 |
| Other assets | - | 0 |
| Accounts payable and accrued expenses | -195,190 | 611,731 |
| Changes in operating right-of-use assets | - | 96,745 |
| Operating lease liabilities | -149,703 | -98,618 |
| Net cash flows used in operating activities | -12,884,867 | -8,312,887 |
| Purchase of property and equipment | 1,714 | 1,159 |
| Purchases of marketable securities | 10,517,490 | 8,440,696 |
| Redemptions of marketable securities | 23,280,231 | 15,274,344 |
| Net cash flows provided by (used in) investing activities | 12,761,027 | 6,832,489 |
| Net proceeds from the issuance of common stock, net of issuance costs of 30,722 | 958,339 | - |
| Proceeds from warrant exercises | - | 0 |
| Proceeds from option exercises | 13,442 | - |
| Net cash flows provided by financing activities | 971,781 | 0 |
| Effect of foreign exchange rates on cash | 30,466 | 30,727 |
| Change in cash and cash equivalents for the period | 878,407 | -1,449,671 |
| Cash and cash equivalents at beginning of period | 7,511,079 | - |
| Cash and cash equivalents at end of period | 8,389,486 | - |
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)